Artificial intelligence is reshaping life sciences by enabling faster hypothesis generation, target discovery, and biomarker identification. Leading firms and scientific teams deploy advanced AI models, including generative foundation models and polygenic scoring algorithms, to tackle complex genetic diseases and optimize drug discovery. The integration of AI platforms such as Nach01 on AWS exemplifies scalable computational tools augmenting molecular simulations and retrosynthesis. These technological advances promise to reduce development timelines and costs across therapeutics and diagnostics.